e-learning
resources
ERJ
2003
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Expression of the serotonin 1b receptor in experimental pulmonary hypertension
Rondelet B., Van Beneden R., Kerbaul F., Motte S., Fesler P., McEntee K., Brimioulle S., Ketelslegers J-M., Naeije R.
Source:
Eur Respir J 2003; 22: 408-412
Journal Issue:
September
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Rondelet B., Van Beneden R., Kerbaul F., Motte S., Fesler P., McEntee K., Brimioulle S., Ketelslegers J-M., Naeije R.. Expression of the serotonin 1b receptor in experimental pulmonary hypertension. Eur Respir J 2003; 22: 408-412
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Current medical therapies in pulmonary arterial hypertension
Source: Eur Respir Mon 2012; 57: 26-41
Year: 2012
Pathophysiology of pulmonary arterial hypertension
Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=191
Year: 2004
Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension
Source: Annual Congress 2005 - Scientific year in review
Year: 2005
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure
Source: Eur Respir J 2011; 37: 578-586
Year: 2011
Single arterial occlusion to locate resistance in patients with pulmonary hypertension
Source: Eur Respir J 2003; 21: 31-36
Year: 2003
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
Source: Eur Respir J 2008; 31: 343-348
Year: 2008
Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension
Source: Eur Respir J 2010; 36: 1483-1485
Year: 2010
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005
Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension
Year: 2007
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Roundabout (Robo) receptors on pulmonary artery endothelial cells: Implications for pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
The interleukin 13 receptor system is altered in pulmonary arterial hypertension
Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling
Year: 2006
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009
Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 1354-1360
Year: 2009
Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target
Source: Eur Respir J 2011; 38: 1453-1460
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept